<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00054405</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00024</org_study_id>
    <secondary_id>NANT 2001-01</secondary_id>
    <secondary_id>CDR0000270447</secondary_id>
    <secondary_id>P01CA081403</secondary_id>
    <secondary_id>CDR0000270447</secondary_id>
    <nct_id>NCT00054405</nct_id>
    <nct_alias>NCT00065494</nct_alias>
  </id_info>
  <brief_title>Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma</brief_title>
  <official_title>A Phase I Investigation of IL-12 (NSC 672423)/Pulse IL-2 (Aldesleukin) in Children With Persistent and/or Refractory Neuroblastoma (13623)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to compare the effectiveness of interleukin-12 with or without interleukin-2 in&#xD;
      treating young patients who have refractory or recurrent neuroblastoma. Biological therapies&#xD;
      use different ways to stimulate the immune system and stop cancer cells from growing.&#xD;
      Combining interleukin-2 with interleukin-12 may kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      I. Define the maximum tolerated dose and dose-limiting toxicity of interleukin-12 with or&#xD;
      without interleukin-2 in patients with refractory or recurrent neuroblastoma.&#xD;
&#xD;
      II. Determine, preliminarily, the antitumor effect of interleukin-12 with or without&#xD;
      interleukin-2 in these patients.&#xD;
&#xD;
      III. Evaluate the immunoregulatory activity of interleukin-12 with or without interleukin-2&#xD;
      in these patients.&#xD;
&#xD;
      IV. Evaluate the antiangiogenic activity of interleukin-12 with or without interleukin-2 in&#xD;
      these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study. Patients are assigned to 1 of 2&#xD;
      treatment cohorts.&#xD;
&#xD;
      COHORT A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8,&#xD;
      10, and 12.&#xD;
&#xD;
      COHORT B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and&#xD;
      8 and IL-12 IV as in cohort A.&#xD;
&#xD;
      Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Some patients may receive additional courses at the&#xD;
      discretion of the principal investigator.&#xD;
&#xD;
      Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the&#xD;
      MTD.&#xD;
&#xD;
      Patients are followed at 3 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) assessed by Common Toxicity Criteria (CTC)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response assessed by Response Evaluation Criteria for Solid Tumors (RECIST)</measure>
    <time_frame>Up to 3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Recurrent Neuroblastoma</condition>
  <arm_group>
    <arm_group_label>Treatment (IL-12, aldesleukin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohort A: Patients receive interleukin-12 (IL-12) IV over 5-15 seconds on days 1, 3, 5, 8, 10, and 12.&#xD;
Cohort B: Patients receive interleukin-2 (IL-2) IV over 15 minutes twice daily on days 1 and 8 and IL-12 IV as in cohort A.&#xD;
Treatment in both cohorts repeats every 28 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Some patients may receive additional courses at the discretion of the principal investigator.&#xD;
Cohorts of 3-6 patients in both cohorts receive escalating doses of IL-2 and IL-12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
Once the MTD is determined, an additional cohort of 8 patients receives IL-12 and IL-2 at the MTD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interleukin-12</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IL-12, aldesleukin)</arm_group_label>
    <other_name>cytotoxic lymphocyte maturation factor</other_name>
    <other_name>IL-12</other_name>
    <other_name>interleukin-12</other_name>
    <other_name>natural killer cell stimulatory factor</other_name>
    <other_name>Ro 24-7472</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (IL-12, aldesleukin)</arm_group_label>
    <other_name>IL-2</other_name>
    <other_name>Proleukin</other_name>
    <other_name>recombinant human interleukin-2</other_name>
    <other_name>recombinant interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of neuroblastoma&#xD;
&#xD;
               -  Histologically confirmed disease AND/OR disease defined by tumor cells in the&#xD;
                  bone marrow and elevated urinary catecholamine metabolites&#xD;
&#xD;
          -  Persistent and/or refractory disease, with at least 1 of the following:&#xD;
&#xD;
               -  Biopsy-proven residual disease at least 12 weeks after myeloablative therapy&#xD;
&#xD;
               -  Progressive disease after nonmyeloablative or myeloablative therapy&#xD;
&#xD;
          -  Recurrent disease, evidenced by any of the following:&#xD;
&#xD;
               -  Biopsy-proven recurrent soft tissue disease&#xD;
&#xD;
               -  Metaiodobenzylguanidine (MIBG)-positive lesions visible on any other imaging&#xD;
                  modality or repeat MIBG obtained 2-4 weeks or more apart&#xD;
&#xD;
               -  Histologically confirmed bone marrow disease&#xD;
&#xD;
               -  Progressive or stable disease after at least 1 prior standard salvage regime&#xD;
&#xD;
          -  No clinically significant pleural effusion&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Life expectancy &gt;= 12 weeks&#xD;
&#xD;
          -  Hepatitis A antibody negative&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
               -  Positive hepatitis B titer allowed if patient has been immunized and has no&#xD;
                  history of disease&#xD;
&#xD;
          -  Hepatitis C virus negative&#xD;
&#xD;
          -  No history of congenital or acquired coagulation disorder&#xD;
&#xD;
          -  Cardiac function normal by ECG&#xD;
&#xD;
          -  No dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  Oxygen saturation at least 94% by pulse oximetry&#xD;
&#xD;
          -  DLCO greater than 60% of predicted&#xD;
&#xD;
          -  FEV1 greater than 70% of predicted&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Skull-based bony lesions without space-occupying intracranial extension are allowed&#xD;
&#xD;
          -  No prior or concurrent intracranial metastatic disease to the brain parenchyma&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for at least 2&#xD;
             months after study&#xD;
&#xD;
          -  No prior hematologic malignancy (including leukemia or lymphoma)&#xD;
&#xD;
          -  No history of malignant hyperthermia&#xD;
&#xD;
          -  No prior or concurrent autoimmune disease&#xD;
&#xD;
          -  No positive direct Coombs testing&#xD;
&#xD;
          -  No history of ongoing or intermittent bowel obstruction&#xD;
&#xD;
          -  No active infection or other significant systemic illness&#xD;
&#xD;
          -  More than 2 weeks since prior fenretinide&#xD;
&#xD;
          -  More than 2 weeks since prior 13-cis-retinoic acid&#xD;
&#xD;
          -  More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)&#xD;
&#xD;
          -  More than 2 weeks since prior interferons or interleukins&#xD;
&#xD;
          -  More than 2 weeks since prior cytokine-fusion proteins&#xD;
&#xD;
          -  More than 2 weeks since prior IV immunoglobulin (IVIG)&#xD;
&#xD;
          -  No prior interleukin-12&#xD;
&#xD;
          -  No concurrent cytokines&#xD;
&#xD;
          -  No concurrent fenretinide&#xD;
&#xD;
          -  No concurrent 13-cis-retinoic acid&#xD;
&#xD;
          -  No other concurrent immunomodulators, including:&#xD;
&#xD;
               -  G-CSF and GM-CSF&#xD;
&#xD;
               -  Interferons&#xD;
&#xD;
               -  Other interleukins&#xD;
&#xD;
               -  IVIG&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No other unstable medical condition or critical illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  More than 12 weeks since prior myeloablative chemotherapy followed by autologous stem&#xD;
             cell transplantation:&#xD;
&#xD;
        No prior myeloablative chemotherapy followed by allogeneic bone marrow transplantation&#xD;
&#xD;
          -  More than 2 weeks since prior growth hormones&#xD;
&#xD;
          -  More than 4 weeks since prior systemic corticosteroids&#xD;
&#xD;
          -  More than 2 weeks since prior non-corticosteroid hormonal therapy (including oral&#xD;
             birth control pills)&#xD;
&#xD;
          -  No concurrent hormonal therapy (including oral birth control pills)&#xD;
&#xD;
          -  No concurrent growth hormones&#xD;
&#xD;
          -  No concurrent systemic corticosteroids, except for use in life-threatening&#xD;
             complications&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior solid organ transplantation&#xD;
&#xD;
          -  More than 4 weeks since prior investigational agents&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No prior enrollment on COG-A3973, unless disease has progressed&#xD;
&#xD;
          -  No history of hemolytic anemia&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3 [Note: Independent of growth factor or&#xD;
             transfusion support]&#xD;
&#xD;
          -  Platelet count at least 75,000/mm^3 [Note: Independent of growth factor or transfusion&#xD;
             support]&#xD;
&#xD;
          -  AST and ALT less than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin less than 2.0 mg/dL&#xD;
&#xD;
          -  Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min OR&#xD;
             creatinine normal&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Ejection fraction at least 50% by echocardiogram or MUGA OR Fractional shortening at&#xD;
             least 30% by echocardiogram&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No uncontrolled cardiac arrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon Wigginton</last_name>
    <role>Principal Investigator</role>
    <affiliation>New Approaches to Neuroblastoma Treatment (NANT)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Approaches to Neuroblastoma Treatment (NANT)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-6016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco - Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0875</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AFLAC Cancer Center and Blood Disorders Service</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Memorial Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan University Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>April 8, 2013</last_update_submitted>
  <last_update_submitted_qc>April 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Interleukin-12</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

